RIO DE JANEIRO, BRAZIL – Brazilian endocrinologist Dr. Flavio Cadegiani and eight other co-authors have published a peer-reviewed scientific study on the efficacy of early treatment with ivermectin against covid-19, involving more than 200,000 people.
“Before the study was published, I was very cautious about the efficacy of ivermectin as part of the treatment against covid-19,” Dr. Cadegiani admits to FranceSoir at the outset.
However, he asserts that he prescribed the drug to prevent the disease because “there is no risk in taking it.” In his opinion, the risk-benefit balance can only be positive since the risk is zero.
(Watch video the entire ivermectin story)
In the empirical study conducted in the heart of the port city of Itajai in southern Brazil, more than 200,000 people were observed, and the results are clear. The risk of infection, severe cases, or mortality is lower:
- 44% reduction in risk of infection;
- 56% reduction in risk of hospitalization (this may be comparable to the severe form of the disease);
- 68% reduction in risk of death
Dr. Cadegiani states that this is the first publication and that four more will follow with data from other countries. He also emphasizes that he has no ties to pharmaceutical laboratories and even says that he contributed 100,000 euros out of his pocket to these various studies to conduct them.
He also used very conservative statistical models to provide the most rigorous evidence possible.
Although it is widely used in India, Japan, and many other countries, ivermectin is not recommended by the World Health Organization (WHO) as part of treatment for covid-19.